Christine McIntyre

849 total citations
31 papers, 634 citations indexed

About

Christine McIntyre is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Christine McIntyre has authored 31 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Genetics. Recurrent topics in Christine McIntyre's work include Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and HER2/EGFR in Cancer Research (9 papers). Christine McIntyre is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and HER2/EGFR in Cancer Research (9 papers). Christine McIntyre collaborates with scholars based in Switzerland, United Kingdom and Canada. Christine McIntyre's co-authors include Beate Bittner, Florence Hourcade‐Potelleret, Christian Schwabe, Vernon Harvey, Chris Wynne, Johannes Schmidt, Claude Berge, Pakeeza Sayyed, Andrew Davies and Olivier Catalani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Christine McIntyre

31 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine McIntyre Switzerland	14	303	253	202	201	146	31	634
Andrea Knapp Switzerland	15	437 1.4×	135 0.5×	553 2.7×	179 0.9×	136 0.9×	45	731
Monika Długosz‐Danecka Poland	13	226 0.7×	66 0.3×	297 1.5×	145 0.7×	68 0.5×	44	485
Sheng Yang China	16	406 1.3×	29 0.1×	289 1.4×	70 0.3×	192 1.3×	105	781
Natalia Zabalegui Spain	13	264 0.9×	140 0.6×	128 0.6×	57 0.3×	261 1.8×	20	621
Iris Isufi United States	12	283 0.9×	27 0.1×	159 0.8×	121 0.6×	150 1.0×	61	535
Radovan Vrḫovac Croatia	15	253 0.8×	29 0.1×	227 1.1×	330 1.6×	157 1.1×	65	810
Sven Borchmann Germany	15	298 1.0×	40 0.2×	375 1.9×	77 0.4×	117 0.8×	46	612
Kevin A. David United States	16	660 2.2×	29 0.1×	417 2.1×	96 0.5×	188 1.3×	41	1.2k
Marek Krogulec United States	6	134 0.4×	38 0.2×	56 0.3×	160 0.8×	194 1.3×	10	675
Joline S.J. Lim Singapore	14	392 1.3×	129 0.5×	49 0.2×	23 0.1×	47 0.3×	56	805

Countries citing papers authored by Christine McIntyre

Since Specialization

Citations

This map shows the geographic impact of Christine McIntyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine McIntyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine McIntyre more than expected).

Fields of papers citing papers by Christine McIntyre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine McIntyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine McIntyre. The network helps show where Christine McIntyre may publish in the future.

Co-authorship network of co-authors of Christine McIntyre

This figure shows the co-authorship network connecting the top 25 collaborators of Christine McIntyre. A scholar is included among the top collaborators of Christine McIntyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine McIntyre. Christine McIntyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sánchez, Javier, Christina Claus, Christine McIntyre, et al.. (2024). Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL. Frontiers in Pharmacology. 15. 1472662–1472662. 1 indexed citations

Claus, Christina, R. Albrecht, Christine McIntyre, et al.. (2023). A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1804–1818. 2 indexed citations

Moisan, Annie, Francesca Michielin, Wolfgang Jacob, et al.. (2018). Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Molecular Cancer Therapeutics. 17(7). 1464–1474. 18 indexed citations

Zhang, Weijiang, Christine McIntyre, Rabab Gaafar, et al.. (2018). Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF^V600 Mutation–Positive Metastatic Malignancy. Clinical Pharmacology in Drug Development. 8(6). 837–843. 6 indexed citations

Ravva, Patanjali, et al.. (2018). A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel. Cancer Chemotherapy and Pharmacology. 82(3). 395–406. 6 indexed citations

Zhang, Weijiang, Christine McIntyre, Tae Min Kim, et al.. (2018). Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF^V600 Mutation–Positive Metastatic Malignancy. The Journal of Clinical Pharmacology. 58(8). 1067–1073. 11 indexed citations

Meneses‐Lorente, Georgina, Christine McIntyre, Joy Hsu, et al.. (2017). Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab. Cancer Chemotherapy and Pharmacology. 79(6). 1239–1247. 3 indexed citations

Davies, Andrew, Claude Berge, Anjum Dadabhoy, et al.. (2017). Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy. 34(10). 2210–2231. 41 indexed citations

Kilburn, Lindsay, Mehmet Koçak, Patricia Baxter, et al.. (2017). A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatric Blood & Cancer. 65(2). 16 indexed citations

10.

Assouline, Sarit, Valéria Buccheri, Alain Delmer, et al.. (2016). Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. The Lancet Haematology. 3(3). e128–e138. 35 indexed citations

11.

Davies, Andrew, Francesco Merli, Biljana Mihaljević, et al.. (2014). Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet Oncology. 15(3). 343–352. 90 indexed citations

12.

Morcos, Peter N., Xiaoping Zhang, Christine McIntyre, et al.. (2013). Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. International Journal of Clinical Pharmacology and Therapeutics. 51(7). 537–548. 19 indexed citations

13.

Bittner, Beate, W. Richter, Florence Hourcade‐Potelleret, et al.. (2013). Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen. Drug Research. 63(11). 602–602. 30 indexed citations

14.

Schmitt, Christophe, et al.. (2012). Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers. International Journal of Clinical Pharmacology and Therapeutics. 50(8). 566–572. 1 indexed citations

15.

Bittner, Beate, Christine McIntyre, Wantanee Phuapradit, et al.. (2012). Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).. PubMed. 67(3). 233–41. 15 indexed citations

16.

McIntyre, Christine, et al.. (2012). Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age. Thrombosis and Haemostasis. 108(7). 54–64. 1 indexed citations

17.

Bittner, Beate, Christine McIntyre, Paul Jordan, & Johannes Schmidt. (2012). Drug-drug interaction study between a novel oral ibandronate formulation and metformin. Arzneimittelforschung. 61(12). 707–713. 4 indexed citations

18.

Wynne, Chris, et al.. (2012). Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer. The Journal of Clinical Pharmacology. 53(2). 192–201. 107 indexed citations

19.

Salar, Antonio, Irit Avivi, Jean-François Larouche, et al.. (2012). Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL). Blood. 120(21). 1641–1641. 7 indexed citations

20.

Schmitt, Christophe, et al.. (2011). Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 52(4). 499–510. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact